Literature DB >> 25394159

Central nervous system penetration-effectiveness rank does not reliably predict neurocognitive impairment in HIV-infected individuals.

Raffaella Libertone1, Patrizia Lorenzini1, Pietro Balestra1, Carmela Pinnetti1, Martina Ricottini1, Maria Maddalena Plazzi1, Samanta Menichetti1, Mauro Zaccarelli1, Emanuele Nicastri1, Rita Bellagamba1, Adriana Ammassari1, Andrea Antinori1.   

Abstract

INTRODUCTION: Central nervous system (CNS) penetration-effectiveness (CPE) rank was proposed in 2008 as an estimate of penetration of ARV regimen into the CNS, and validated as predictor of CSF HIV-1 replication. RESULTS on predictive role of CPE on neurocognitive and clinical outcome were conflicting.
MATERIALS AND METHODS: Retrospective, cross-sectional analysis of neurocognitive profile in HIV-infected cART-treated patients. All patients underwent neuropsychological (NP) assessment by standardized battery of 14 tests on 5 different domains. People were classified as having NCI if they scored >1 standard deviation (SD) below the normal mean in at least two tests, or >2 SD below in one test. Linear and logistic regression analyses were fitted using as outcome Npz8 and impaired/not impaired respectively.
RESULTS: A total of 660 HIV-infected cART-treated individuals from 2009 to 2014, contributing a total of 1003 tests (mean age 49 (IQR 43-56), male 82%; median current CD4 586/mm(3); 18% HCV infected; HIV-RNA <40 cp/mL in 84%). Current ARV regimen was 2NRTIs+1NNRTI 50.3%, 2NRTI+1PI/r in 32.6%, NRTI sparing in 11.1%. Mean CPE of current regimens was 6.6 (95% CI 6.5-6.7). As per test multivariable analysis, higher CPE values were associated to poor NP tasks (Beta=-0,09; 95% CI -0,14 -0,03; p=0.002 at multivariable linear regression). The association between higher CPE and increased NCI risk was confirmed at multivariable logistic regression, with a 1.24-fold risk of NCI occurrence for each point increase of CPE of current regimen at the time of NP testing (see Table 1). In a sensitivity analysis performed only on patients at the first NP test, the association between higher CPE and poor NP tasks and enhanced NCI risk was only marginally confirmed (Beta=-0,05; [-0,12-0,02]; p=0,19; OR 1,13 [0,95-1,34]; p=0.17). Older age, longer time from HIV diagnosis, current CD4 count <350 cell/mm(3) and lower education level were all associated to an increased risk of NCI.
CONCLUSIONS: In our analysis, higher CPE rank is associated to poorly performing at NP tasking. Even if selection bias could not be excluded due to retrospective cross-sectional design, these results fitted with the direct correlation between high CPE and HIV dementia recently recorded in a large observational database. We think that CPE use to guide ART in patients neurocognitively impaired should be revised.

Entities:  

Year:  2014        PMID: 25394159      PMCID: PMC4225401          DOI: 10.7448/IAS.17.4.19655

Source DB:  PubMed          Journal:  J Int AIDS Soc        ISSN: 1758-2652            Impact factor:   5.396


Multivariable analysis of predictors of neurocognitive impairment by logistic regression model
Table 1

Multivariable analysis of predictors of neurocognitive impairment by logistic regression model

Multivariable logistic regressionOR95%CIp
Age (per 10 years incr.)1.041.021.050.000
Mode of HIV transmission
 Heterosexual1.00
 Homosexual1.140.811.590.459
 IVDU0.940.511.740.855
Other/unknown0.930.441.950.841
Previous aids event1.720.773.840.186
Years from HIV test (per one year incr.)1.041.021.070.000
HIV-RNA <40 cp/mL at NPA0.700.451.070.102
CD4 at NPA, cell/mmc
  > 5001.00
 350–5002.201.423.420.000
  < 3501.571.072.300.021
Education (per one year more)0.830.800.870.000
HCV co-infection
 Negative1.00
 Positive1.290.822.030.269
 Unknown1.480.762.880.254
Type of current regimen
 NRTI + NNRTI1.00
 NRTI + PIB1.300.921.850.135
 NRTI + II1.700.535.410.369
 NTRI sparing1.090.562.150.792
 Other0.810.381.760.599
CPE 20101.231.071.410.003
  7 in total

1.  Interaction Effects between HIV and Aging on Selective Neurocognitive Impairment.

Authors:  Yingying Ding; Haijiang Lin; Weiwei Shen; Qionghai Wu; Meiyang Gao; Na He
Journal:  J Neuroimmune Pharmacol       Date:  2017-05-03       Impact factor: 4.147

Review 2.  Neurologic Complications in Treated HIV-1 Infection.

Authors:  Nisha S Bhatia; Felicia C Chow
Journal:  Curr Neurol Neurosci Rep       Date:  2016-07       Impact factor: 5.081

Review 3.  Neurologic Complications of Human Immunodeficiency Virus Infection.

Authors:  Deanna Saylor
Journal:  Continuum (Minneap Minn)       Date:  2018-10

Review 4.  Clinical Treatment Options and Randomized Clinical Trials for Neurocognitive Complications of HIV Infection: Combination Antiretroviral Therapy, Central Nervous System Penetration Effectiveness, and Adjuvants.

Authors:  Shih-Ping Lin; Andrea Calcagno; Scott L Letendre; Qing Ma
Journal:  Curr Top Behav Neurosci       Date:  2021

5.  Antineuroinflammatory drugs in HIV-associated neurocognitive disorders as potential therapy.

Authors:  Björn Ambrosius; Ralf Gold; Andrew Chan; Simon Faissner
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-04-04

6.  Differential Diagnosis of Chorea-HIV Infection Delays Diagnosis of Huntington's Disease by Years.

Authors:  Jannis Achenbach; Simon Faissner; Carsten Saft
Journal:  Brain Sci       Date:  2021-05-27

7.  Cognitive trajectories over 4 years among HIV-infected women with optimal viral suppression.

Authors:  Leah H Rubin; Pauline M Maki; Gayle Springer; Lorie Benning; Kathryn Anastos; Deborah Gustafson; Maria C Villacres; Xiong Jiang; Adaora A Adimora; Drenna Waldrop-Valverde; David E Vance; Hector Bolivar; Christine Alden; Eileen M Martin; Victor G Valcour
Journal:  Neurology       Date:  2017-09-13       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.